Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma - Chapman, P B; Hauschild, A; Robert, C (ASCO Annual Meeting Plenary Session including Science of Oncology Award and Lecture, 2011)
et al.